Welcome to our dedicated page for ClearPoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on ClearPoint Neuro stock.
ClearPoint Neuro, Inc. (symbol: CLPT) is a leading medical device company based in the United States, specializing in the development and commercialization of innovative platforms designed for performing minimally invasive surgical procedures in both the brain and heart, utilizing magnetic resonance imaging (MRI) guidance. Since its inception in 1998, ClearPoint Neuro has been at the forefront of interventional MRI research and product development.
The company's flagship product, the ClearPoint® System, is currently being used in the United States for minimally invasive brain surgeries. This system allows for precision and real-time visualization during complex neurosurgical procedures, significantly improving patient outcomes. The ClearTrace® System, still under development, aims to bring similar advancements to cardiac surgeries, offering minimally invasive solutions for heart procedures.
ClearPoint Neuro's product portfolio includes the ClearPoint System, ClearPoint Services, and ClearPoint Therapeutic Solutions. Their latest innovation, the Prism Neuro Laser Therapy System, received FDA clearance and has been integrated with the company's SmartFrame Array® 1.2 software, enhancing the practicality and efficiency of neuro laser therapies. This integration allows for combined biopsy and laser therapy procedures to be performed in a single setting, reducing setup times and improving procedural accuracy.
Financially, ClearPoint Neuro has shown robust growth. In the fourth quarter of 2023, the company reported a record revenue of $6.8 million, marking a 30% increase. Their strategic partnerships, including those with clinical and pharmaceutical firms, further bolster their financial stability and market reach. The recent equity offering of approximately $15 million has solidified their balance sheet, reinforcing investor confidence in their continued growth and innovation.
ClearPoint Neuro is also deeply involved in advancing gene and cell therapy. Their SmartFlow® Cannula is a key device used globally for delivering approved gene therapies directly to the brain. This device has been instrumental in numerous clinical trials, including those for treating AADC deficiency and Frontotemporal Dementia (FTD).
Overall, ClearPoint Neuro remains committed to driving innovation in the medical field, with a strong focus on improving surgical outcomes through advanced imaging and precise navigation technologies. For more information, visit their website at www.clearpointneuro.com.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the appointment of Lynnette C. Fallon to its Board of Directors effective immediately. Fallon, currently Executive VP and General Counsel at Axcelis Technologies, brings over two decades of experience in business development, financial management, and corporate compliance. President and CEO Joe Burnett expressed optimism about her contributions to human resources and investor relations. ClearPoint Neuro aims to improve treatments for neurological disorders with its FDA-cleared ClearPoint Navigation System, which is operational in over 60 sites worldwide.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the installation of its version 2.0 software at Mazowiecki Szpital Bródnowski in Warsaw, Poland. This milestone allows for advanced procedures including deep brain stimulation, biopsies, and clinical trials. Professor Mirosław Ząbek praised the ClearPoint team's dedication during installation, anticipating significant clinical advancements. Matt Rabon emphasized the importance of Poland's clinical trial market and the ongoing strategy to expand ClearPoint’s drug delivery trial centers in Europe as COVID-19 restrictions ease.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) will join the Russell 3000 Index effective June 28, 2021. This addition, announced in a preliminary list on June 4, will enhance the company's institutional shareholder base and visibility among investors. The Russell 3000 Index includes the largest U.S. stocks by market capitalization, facilitating investment strategies for a significant number of fund managers. ClearPoint Neuro develops advanced navigation and delivery systems for complex neurological therapies, with FDA-approved products currently operating at over 60 sites globally.
ClearPoint Neuro has achieved a significant milestone by treating the first patient using its platform in a Phase 1 clinical trial for advanced Parkinson's disease. Conducted by BlueRock Therapeutics, this trial investigates the safety and efficacy of pluripotent stem cell-derived dopaminergic neurons. The surgery was performed at Memorial Sloan Kettering Cancer Center, utilizing the ClearPoint Neuro Navigation System. This trial aims to enroll ten patients across sites in the U.S. and Canada, highlighting ClearPoint's role in advancing treatments for complex neurological conditions.
ClearPoint Neuro (Nasdaq: CLPT) will present at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 12:00 p.m. Eastern Time. The presentation aims to showcase the company’s advancements in neurological therapies.
The session will be available to watch on-demand for 30 days on ClearPoint Neuro's website, specifically in the Investor Relations section. ClearPoint focuses on delivering therapies for complex neurological disorders using its Navigation System, which has over 4,500 successful procedures and partnerships with over 30 companies in the pharmaceutical and biotechnology sectors.
ClearPoint Neuro has announced the first human cases using its SmartFrame Array Neuro Navigation System, aiming to enhance neurosurgery workflows by reducing procedure times in MRI and Operating Room settings. The Array system's flexibility is expected to increase accessibility for hospitals and surgeons. Initial procedures were conducted by prominent neurosurgeons at renowned institutions, showcasing the system's efficiency. Full market release of the Array is anticipated in early 2022, following a phase of limited market release to gather training materials and case studies.
ClearPoint Neuro reported Q1 2021 revenue of $4.0 million, up 29% year-over-year. Biologics and drug delivery revenue surged 61% to $1.7 million. The company added new partnerships, raising its total to approximately 30. Case volume increased to 214, exceeding previous estimates. Following a public offering, net proceeds reached $46.8 million, bolstering cash reserves to nearly $65.0 million. Despite hospital budget constraints, the company anticipates 2021 revenues between $16.0 million and $17.5 million.
ClearPoint Neuro (Nasdaq: CLPT) announced a partnership with D&K Engineering to develop a robotic system for MRI and operating room use. This collaboration aims to streamline neurosurgery, enhancing procedural efficiency and patient interaction. The partnership leverages ClearPoint's existing technology and D&K's expertise in medical devices. The robotic system is expected to see its first clinical application in 2023. ClearPoint Neuro's platform has FDA clearance and is already implemented in over 60 clinical sites across the U.S., Canada, and Europe.
ClearPoint Neuro (Nasdaq: CLPT) announced its Q1 2021 financial results release date set for May 11, 2021, after market close. The live broadcast for the results will occur at 4:30 PM ET on the same day. Interested parties can access the call online or by phone. ClearPoint Neuro focuses on improving patient quality of life through precise therapies for neurological disorders, with FDA-cleared products used in over 60 clinical sites. The company’s partnerships include 25 biologics and drug delivery companies, supporting over 4,000 cases.
ClearPoint Neuro (CLPT) announced its support for Voyager Therapeutics' FDA clearance of the IND application for the gene therapy candidate VY-HTT01, aimed at treating Huntington’s disease, affecting around 30,000 people in the U.S. This gene therapy will undergo a Phase 1/2 clinical trial to assess its safety and tolerability. ClearPoint's navigation and delivery systems play a crucial role in this trial. The company remains committed to innovating and providing clinical services that support complex neurological treatments.
FAQ
What is the current stock price of ClearPoint Neuro (CLPT)?
What is the market cap of ClearPoint Neuro (CLPT)?
What does ClearPoint Neuro, Inc. do?
What is the ClearPoint® System?
Is the ClearTrace® System available?
What recent advancements has ClearPoint Neuro made?
What financial achievements did ClearPoint Neuro report in the fourth quarter of 2023?
What is the SmartFlow® Cannula used for?
How does ClearPoint Neuro contribute to gene and cell therapy?
Where can I find more information about ClearPoint Neuro?
How has ClearPoint Neuro's financial status improved recently?
What is the significance of the Prism Neuro Laser Therapy System?
